Pure Global AI
NCT06386146Not yet recruiting

JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-30355 in Adult Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
Jacobio Pharmaceuticals Co., Ltd.Phase 1/2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Solid Tumors
Drug/Device/Intervention
JAB-30355
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Jacobio Pharmaceuticals Co., Ltd.
Timeline & enrollment
Phase
Phase 1/2
Start date
Jul 01, 2024
End date
Jul 01, 2027
Enrollment
144 participants
Primary outcome

Dose limiting toxicity (DLT),Number of participants with adverse events

Summary

This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with
 advanced solid tumors harboring TP53 Y220C mutation.

ICD-10 classifications
Malignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm of other connective and soft tissueCarcinoma in situ, unspecifiedMalignant neoplasmsMalignant neoplasm: Parametrium
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06386146
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06386146 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Jacobio Pharmaceuticals Co., Ltd. and is currently Not yet recruiting. The study focuses on Solid Tumors. Target enrollment is 144 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.